Table 1. The effect of HIV-1 Tat on parameters of DRG excitability.
| Control | 2 min | 4 min | 6 min | 10 min | 15 min | |
| Tat (20 μM) | ||||||
| RMP (mV) | −50±0.8 | −48±0.8** | −48±0.8** | −47±0.3** | −46±0.4** | −45±0.4** |
| FT (mV) | −12.4±0.7 | −13.1±0.8 | −12.9±1.0 | −12.9±1.0 | −12.7±0.8 | −11.8±0.9 |
| Rheobase (pA) | 306±39 | 252±32** | 246±36** | 219±23** | 207±27** | 213±30** |
| Normalized rheobase | 1.0±0 | 0.84±0.04** | 0.79±0.05** | 0.75±0.05** | 0.69±0.05** | 0.70±0.05** |
| RTh (MΩ) | 146±55 | 162±62 | 181±81 | 177±68 | 194±84** | 198±97** |
| Normalized RTh | 1.0±0 | 0.84±0.04 | 0.79±0.05 | 0.75±0.05 | 0.69±0.05** | 0.70±0.05** |
| Tat (1 μM) | ||||||
| RMP (mV) | −54±1.2 | −50±1.1 | −53±1.6 | −56±1.2 | −49±0.8* | −51±1.2 |
| FT (mV) | −16.3±1.9 | −18.1±2.0 | −19.7±2.1 | −17.1±2.1 | −15.7±1.8 | −16.7±2.1 |
| Rheobase (pA) | 388±51 | 352±58 | 272±36 | 246±35 | 229±38 | 349±63 |
| Normalized rheobase | 1.0±0 | 0.91±0.08 | 0.74±0.11 | 0. 67±0.10 | 0.65±0.13 | 0.91±0.09 |
| RTh (MΩ) | 104±10.7 | 105±16.6 | 139±27.7 | 192±49.3 | 192±49.7 | 114±18.3 |
| Normalized RTh | 1.0±0 | 0.84±0.04 | 0.79±0.05 | 0.75±0.05 | 0.69±0.05 | 0.70±0.05 |
| Inactivated Tat (μM) | ||||||
| RMP (mV) | −52±1.0 | −51±1.1 | −49±1.4 | −50±1.1 | −49±1.1 | −51±1.4 |
| FT (mV) | −11.9±1.5 | −12.2±1.8 | −13.4±1.7 | −11.3±2.0 | −10.6±2.5 | −9.6±2.8 |
| Rheobase (pA) | 392±51 | 382±49 | 378±52 | 380±59 | 373±39 | 423±48 |
| Normalized rheobase | 1.0±0 | 0.99±0.06 | 0.99±0.08 | 0.99±0.10 | 1.01±0.09 | 1.11±0.06 |
| RTh (MΩ) | 119±22 | 117±22 | 106±14 | 119±21 | 111±15 | 107±17 |
| Normalized RTh | 1.0±0 | 0.99±0.04 | 0.94±0.07 | 1.04±0.13 | 0.99±0.11 | 0.93±0.08 |
RMP: resting membrane potential; FT: firing threshold; RTh: resistance at threshold. Normalized rheobase: rheobase was normalized to the control. Normalized RTh: RTh was normalized to the control. Data are expressed as mean ± S.E.M. N = 15.
*p<0.05;
**p<0.01. Groups were compared with controls by Anova or Repeated Measures Anova.